RxDoctor Payments Data

Katarzyna Schuld, MD

Sleep Medicine · Schaumburg, ILNPI 1609258102

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,823 of the $3,353 with a category attached, or 84.2%. It is spread thinly across 18 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,360 and has fallen 68.7% since, to $426 in 2025.

$3,353in general payments, 2019–2025

Across 143 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$738
  • GSK$462
  • AstraZeneca$357
  • Inspire Medical Systems, Inc.$266
  • Boehringer Ingelheim$203
  • Harmony Biosciences LLC$177
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$1504%
  • Food & beverage$2,82384%
  • Education$38011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,353 in reported general payments places this provider in the 70th percentile of 79 sleep medicine providers in Illinois.

See all sleep medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$116,793
Medicare patients
671
Services billed
1,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SunosiSolriamfetol Hcl11$9,430
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate20$6,523
Doxepin Hcl46$3,505
Eszopiclone39$1,462
Modafinil29$1,082
Gabapentin80$683
Zolpidem Tartrate83$508
Pregabalin12$477
Pramipexole DihydrochloridePramipexole Di-Hcl38$418
Ropinirole Hcl18$399
Trazodone Hcl60$370
Zaleplon24$210
Clonazepam24$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Sunosi$90$9,43011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 sleep medicine providers in Illinois.

Other sleep medicine in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →